Hayden Panettiere’s death draws fresh backlash on Neutrogena amid claims of a canceled contract

Hayden Panettiere’s death sparked renewed public attention on Neutrogena on Aug. 18, according to a report by the New York Post, with some fans saying they would stop buying the face-wash brand over a dispute they trace to 2015. The controversy centers on Panettiere’s prior comments about her relationship with Neutrogena. In the years-old account highlighted by the Post, Panettiere said she was “released” from a Neutrogena contract after speaking up about postpartum depression. The reporting frames the renewed reaction as an emotional reexamination of that alleged breakdown and a renewed wave of online calls to boycott. The Post also reported that Neutrogena-related discussion accelerated quickly after Panettiere’s death, describing what it characterized as a stock drop tied to the online backlash. The report presented the market reaction as part of the broader consumer pressure campaign, but did not, in the information provided here, include specific figures or a detailed explanation from Neutrogena or its parent company about the original contract decision or any connection between the two events. On social media, fans cited Panettiere’s past statements as part of why they would not purchase Neutrogena products again. The Post quoted vows from commenters, including one user saying, “I will never buy again,” and described a wider pattern of boycott language that the report says is being coordinated around the brand’s alleged conduct during the earlier dispute. The 2015 dispute, as characterized in the Post’s account, appears to be less about current product safety and more about how an entertainment figure’s public comments were handled in a commercial relationship, including whether speaking out on postpartum depression affected the contract status. That distinction matters for consumers and regulators, because the claims described in the report relate to contractual and communications decisions rather than to any asserted harm from a specific Neutrogena formulation. Neutrogena’s response to Panettiere’s account is not reflected in the information provided with this discovery packet. Without additional documentation from Neutrogena, Panettiere’s representatives, or filings around the contract itself, it is not possible to independently verify the company’s reasoning for any alleged termination or release, or to confirm the causal link between fan posts and the reported market movement. The next practical steps will likely depend on whether the brand or its corporate parent addresses the underlying 2015 claims and clarifies whether any contracts were changed, ended, or otherwise restructured. For consumers, the immediate effect is a renewed boycott push driven by audience reaction, while for the company the pressure point is reputational and customer-retention risk tied to contract narratives resurfacing after a celebrity death.